Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed

Bioventus Inc.

2025-Q1 EPS reported -$0.04 revenue$123,876,000

Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.
Non-GAAP EPS $0.08, up 33% YoY; Adjusted EBITDA $19.2M vs $22.6M prior due to divestiture.
Pain Treatments +3.9%, Surgical Solutions +7.0%, Restorative Therapies -35.3% (reflecting rehab divestiture).
FY2025 guidance reaffirmed: revenue $560-570M, Adj. EBITDA $112-116M, Non-GAAP EPS $0.64-0.68.
Entered distribution agreement for XCELL PRP system; added new senior leaders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.